OBX
Obsidian Therapeutics, Inc.
Set alert
- YTD
- -15.49%
- 1 year
- -15.49%
- Open
- 14.55
- Prev close
- 14.52
- Mkt cap
- 913.62M
- Vol
- 563.09K
- Avg vol
- 378.15K
- EPS
- -1.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.66
- High
- 15.48
- Forward P/E
- -7.98
- Beta
- 2.60
- Short ratio
- 0.69
- Inst. own
- 27.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 31, 2025
- 50-d avg
- 19.99
- 200-d avg
- 19.99
- 1y target
- 39.00
News
4 weeks ago gurufocus.com
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop
-
4 weeks ago benzinga.com
Obsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Its Phase 1 Study And The Phase 1/2 Agni-01 Multicenter Study Of Amsokigene Autoleucel
Presentations at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, AZ, November 4-8, 2026. The poster presentation will summarize pooled safety data across…
4 weeks ago businesswire.com
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop…
1 month ago defenseworld.net
Obsidian Therapeutics (NASDAQ:OBX) Short Interest Update
Obsidian Therapeutics (NASDAQ: OBX - Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling…
-
1 month ago benzinga.com
Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32
Leerink Partners initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Outperform rating and announces Price Target of $32.
1 month ago seekingalpha.com
Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error
Obsidian Therapeutics is rated Hold due to overvaluation despite promising cell therapy technology targeting solid tumors. OBX-115, the lead asset, shows strong early efficacy and safety in advanced…
1 month ago benzinga.com
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.
2 months ago benzinga.com
Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday
US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's after-market session. The company's market cap stands at $4.9 million. Quanterix (NASDAQ:QTRX) shares…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
2 months ago 247wallst.com
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most…
2 months ago benzinga.com
This Civeo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Analysts change outlook on top Wall Street names, including initiations, upgrades, and downgrades. Check our analyst ratings page for details.
-
2 months ago benzinga.com
Obsidian Therapeutics Enrolls First Participant In Its Phase 1/2 Agni-01 Trial Of Amsokigene Autoleucel To Treat Advanced Or Metastatic Melanoma
Obsidian Therapeutics, Inc. ("Obsidian") (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte…
2 months ago businesswire.com
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop…
-
2 months ago benzinga.com
Piper Sandler Initiates Coverage On Obsidian Therapeutics with Overweight Rating, Announces Price Target of $42
Piper Sandler analyst Kelsey Goodwin initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Overweight rating and announces Price Target of $42.
2 months ago businesswire.com
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop…